Scholarlink

<p>Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The PSYSCAN project aimed to enhance predictive value by integrating data across clinical, environmental, neuroimaging, cognitive, and peripheral blood biomarkers. PSYSCAN employed a naturalistic, prospective design across 12 sites (Europe, Australia, Asia, Americas). Assessments were conducted at baseline, 3, 6, and 12 months, with follow-ups at 18 and 24 months to evaluate clinical and functional outcomes. The study included 238 CHR individuals and 134 healthy controls (HC). At baseline, CHR and HC groups differed significantly in age, education, IQ, and vocational and relationship status. Cannabis and tobacco use did not significantly differ between groups, however CHR individuals had higher proportion of moderate to high risk of tobacco abuse. A substantial portion of the CHR sample met DSM criteria for anxiety (53.4%) and/or mood disorders (52.9%), with some prescribed antidepressants (38.7%), antipsychotics (13.9%), or benzodiazepines (16.4%). Over the follow-up period, 25 CHR individuals (10.5%) transitioned to psychosis. However, the CHR group as a whole showed improvements in functioning and attenuated psychotic symptoms. Similar to other recent multi-centre studies, the CHR cohort exhibits high comorbidity rates and relatively low psychosis transition rates. These findings highlight the clinical heterogeneity within CHR populations and suggest that outcomes extend beyond psychosis onset, reinforcing the need for broader prognostic models that consider functional and transdiagnostic outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月17日

查看全文
  • Stefania Tognin,
  • Sandra Vieira,
  • Dominic Oliver,
  • Alexis E. Cullen,
  • Mathew J. Kempton,
  • Paolo Fusar-Poli,
  • Andrea Mechelli,
  • Paola Dazzan,
  • Kate Merritt,
  • Arija Maat,
  • Lieuwe de Haan,
  • Stephen M. Lawrie,
  • Thérèse van Amelsvoort,
  • Celso Arango,
  • Barnaby Nelson,
  • Silvana Galderisi,
  • Rodrigo Bressan,
  • Jun Soo Kwon,
  • Romina Mizrahi,
  • Paolo Fusar-Poli,
  • Matthew Kempton,
  • Gemma Modinos,
  • Helen Baldwin,
  • Kate Merritt,
  • Fiona Coutts,
  • Emily Hird,
  • Paola Dazzan,
  • George Gifford,
  • Natalia Petros,
  • Mathilde Antoniades,
  • Andrea De Micheli,
  • Sandra Vieira,
  • Tom Spencer,
  • Rene Kahn,
  • Erika van Hell,
  • Inge Winter,
  • Lieuwe de Haan,
  • Frederike Schirmbeck,
  • Benedicto Crespo-Facorro,
  • Diana Tordesillas-Gutierrez,
  • Esther Setien-Suero,
  • Rosa Ayesa-Arriola,
  • Paula Suarez-Pinilla,
  • Victor Ortiz Garcia-de la foz,
  • Birte Glenthøj,
  • Mikkel Erlang Sørensen,
  • Bjørn H. Ebdrup,
  • Karen Tangmose,
  • Helle Schæbel,
  • Egill Rostrup,
  • Stephen Lawrie,
  • Colm McDonald,
  • Brian Hallahan,
  • Dara Cannon,
  • James McLoughlin,
  • Martha Finnegan,
  • Oliver Gruber,
  • Anja Richter,
  • Bernd Krämer,
  • Therese van Amelsvoort,
  • Bea Campforts,
  • Machteld Marcelis,
  • Claudia Vingerhoets,
  • Celso Arango,
  • Covandonga M. Díaz-Caneja,
  • Miriam Ayora,
  • Joost Janssen,
  • Roberto Rodríguez-Jiménez,
  • Marina Díaz-Marsá,
  • Tilo Kircher,
  • Irina Falkenberg,
  • Florian Bitsch,
  • Jens Sommer,
  • Patrick McGorry,
  • Paul Amminger,
  • Meredith McHugh,
  • Silvana Galderisi,
  • Armida Mucci,
  • Paola Bucci,
  • Giuseppe Piegari,
  • Daria Pietrafesa,
  • Sara Patriarca,
  • André Zugman,
  • Ary Gadelha,
  • Graccielle Rodrigues da Cunha,
  • Kang Ik Kevin Cho,
  • Tae Young Lee,
  • Minah Kim,
  • Sun-Young Moon,
  • Silvia Kyungjin Lho,
  • Mark Weiser,
  • Romina Mizrahi,
  • Michael Kiang,
  • Cory Gerritsen,
  • Margaret Maheandiran,
  • Sarah Ahmed,
  • Ivana Prce,
  • Jenny Lepock,
  • Gabriele Sachs,
  • Matthäus Willeit,
  • Marzena Lenczowski,
  • Ullrich Sauerzopf,
  • Ana Weidenauer,
  • Julia Furtner-Srajer,
  • Matthias Kirschner,
  • Anke Maatz,
  • Achim Burrer,
  • Philipp Stämpfli,
  • Naemi Huber,
  • Wolfram Kawohl,
  • Rene S. Kahn,
  • Philip McGuire

摘要

Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The PSYSCAN project aimed to enhance predictive value by integrating data across clinical, environmental, neuroimaging, cognitive, and peripheral blood biomarkers. PSYSCAN employed a naturalistic, prospective design across 12 sites (Europe, Australia, Asia, Americas). Assessments were conducted at baseline, 3, 6, and 12 months, with follow-ups at 18 and 24 months to evaluate clinical and functional outcomes. The study included 238 CHR individuals and 134 healthy controls (HC). At baseline, CHR and HC groups differed significantly in age, education, IQ, and vocational and relationship status. Cannabis and tobacco use did not significantly differ between groups, however CHR individuals had higher proportion of moderate to high risk of tobacco abuse. A substantial portion of the CHR sample met DSM criteria for anxiety (53.4%) and/or mood disorders (52.9%), with some prescribed antidepressants (38.7%), antipsychotics (13.9%), or benzodiazepines (16.4%). Over the follow-up period, 25 CHR individuals (10.5%) transitioned to psychosis. However, the CHR group as a whole showed improvements in functioning and attenuated psychotic symptoms. Similar to other recent multi-centre studies, the CHR cohort exhibits high comorbidity rates and relatively low psychosis transition rates. These findings highlight the clinical heterogeneity within CHR populations and suggest that outcomes extend beyond psychosis onset, reinforcing the need for broader prognostic models that consider functional and transdiagnostic outcomes.